Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials
Dulanji Kuruppu(Eli Lilly (United States)), Susan Hutchinson(Albert Einstein College of Medicine), Yanhong Dong(National University of Singapore), Amy J. Kovacik(Eli Lilly (United States)), Eric Pearlman(University of California, San Francisco), James North(Carolinas Pain Institute)
Cited by 17
Related Papers
Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-induced Tissue Eosinophilia
|The Journal of Experimental Medicine|1997|532
N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis
|Nature Communications|2020|453
Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP
|Nature Communications|2016|446